Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| basal cell | 9 studies | 28% ± 17% | |
| endothelial cell | 6 studies | 20% ± 7% | |
| ciliated cell | 5 studies | 41% ± 24% | |
| CD4-positive, alpha-beta T cell | 3 studies | 18% ± 2% | |
| hematopoietic precursor cell | 3 studies | 16% ± 1% | |
| epithelial cell | 3 studies | 48% ± 32% | |
| retinal pigment epithelial cell | 3 studies | 31% ± 11% | |
| pancreatic ductal cell | 3 studies | 32% ± 7% | |
| secretory cell | 3 studies | 32% ± 10% |
Insufficient scRNA-seq data for expression of CITED4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 98% | 560.21 | 176 / 180 | 100% | 326.59 | 429 / 430 |
| pancreas | 100% | 1584.58 | 327 / 328 | 88% | 69.00 | 157 / 178 |
| esophagus | 95% | 801.81 | 1376 / 1445 | 91% | 92.30 | 167 / 183 |
| liver | 100% | 1159.81 | 225 / 226 | 85% | 98.08 | 344 / 406 |
| uterus | 99% | 832.50 | 169 / 170 | 84% | 88.65 | 385 / 459 |
| kidney | 99% | 1089.30 | 88 / 89 | 84% | 67.95 | 753 / 901 |
| breast | 96% | 1941.60 | 441 / 459 | 81% | 134.38 | 900 / 1118 |
| bladder | 95% | 494.00 | 20 / 21 | 66% | 50.92 | 333 / 504 |
| prostate | 99% | 988.27 | 243 / 245 | 61% | 25.07 | 308 / 502 |
| thymus | 93% | 440.36 | 610 / 653 | 65% | 30.26 | 393 / 605 |
| stomach | 92% | 585.42 | 332 / 359 | 58% | 35.49 | 167 / 286 |
| lung | 92% | 628.80 | 532 / 578 | 50% | 31.59 | 578 / 1155 |
| intestine | 78% | 1013.86 | 754 / 966 | 51% | 29.51 | 271 / 527 |
| adrenal gland | 98% | 801.93 | 254 / 258 | 21% | 10.03 | 49 / 230 |
| ureter | 0% | 0 | 0 / 0 | 100% | 587.99 | 1 / 1 |
| spleen | 100% | 1658.75 | 240 / 241 | 0% | 0 | 0 / 0 |
| muscle | 98% | 777.14 | 785 / 803 | 0% | 0 | 0 / 0 |
| heart | 96% | 758.44 | 824 / 861 | 0% | 0 | 0 / 0 |
| skin | 77% | 1869.30 | 1385 / 1809 | 19% | 12.61 | 88 / 472 |
| blood vessel | 94% | 645.53 | 1261 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 87% | 465.45 | 1046 / 1204 | 0% | 0 | 0 / 0 |
| brain | 81% | 352.10 | 2134 / 2642 | 6% | 2.24 | 40 / 705 |
| tonsil | 0% | 0 | 0 / 0 | 71% | 49.09 | 32 / 45 |
| peripheral blood | 53% | 239.94 | 491 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 11% | 3.82 | 9 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0043627 | Biological process | response to estrogen |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0003713 | Molecular function | transcription coactivator activity |
| Gene name | CITED4 |
| Protein name | Cbp/p300-interacting transactivator 4 (MSG1-related protein 2) (MRG-2) |
| Synonyms | MRG2 |
| Description | FUNCTION: Acts as a transcriptional coactivator for TFAP2/AP-2. Enhances estrogen-dependent transactivation mediated by estrogen receptors. May function as an inhibitor of transactivation by HIF1A by disrupting HIF1A interaction with CREBBP. May be involved in regulation of gene expression during development and differentiation of blood cells, endothelial cells and mammary epithelial cells. . |
| Accessions | ENST00000372638.4 Q96RK1 |
